Financial reports
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-K/A
2021 FY
Annual report (amended)
27 May 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan
12 Mar 24
8-K
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC
27 Feb 24
8-K
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data
5 Feb 24
8-K
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC
9 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Oct 23
8-K
Other Events
26 Sep 23
8-K
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
9 May 23
8-K
Other Events
1 May 23
Registration and prospectus
S-8
Registration of securities for employees
27 Feb 24
S-3ASR
Automatic shelf registration
27 Mar 23
S-8
Registration of securities for employees
9 Mar 23
424B5
Prospectus supplement for primary offering
25 Jan 23
S-3MEF
Registration of additional securities for an S-3
24 Jan 23
424B5
Prospectus supplement for primary offering
23 Jan 23
424B5
Prospectus supplement for primary offering
14 Jul 22
424B5
Prospectus supplement for primary offering
11 Jul 22
POS EX
Additional exhibits for listing
11 Jul 22
S-8
Registration of securities for employees
1 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
Other
UPLOAD
Letter from SEC
2 Jun 22
EFFECT
Notice of effectiveness
1 Jun 22
CORRESP
Correspondence with SEC
27 May 22
UPLOAD
Letter from SEC
17 May 22
EFFECT
Notice of effectiveness
3 Jun 20
CERT
Certification of approval for exchange listing
1 Jun 20
CORRESP
Correspondence with SEC
29 May 20
CORRESP
Correspondence with SEC
29 May 20
CORRESP
Correspondence with SEC
26 May 20
UPLOAD
Letter from SEC
20 May 20
Ownership
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G
First Light Asset Management, LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Third Rock Ventures III, L.P.
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
Laurion Capital Management LP
8 Feb 24
SC 13G
BlackRock Inc.
25 Jan 24